Recently, the Economic Information Daily reported in the article 'Economic Survey: Some pharmaceutical company Dealers are fraudulently issuing invoices forming illegal profit chains'. In 2022 and 2024, law enforcement agencies successively uncovered two cases of fraudulent invoicing in the pharmaceutical field. The investigation found that 'some pharmaceuticals have two sets of prices, namely 'base price' and 'invoice price.' 'Pharmaceutical companies first sell pharmaceuticals to Dealers at the 'invoice price,' and then the Dealers sell them to Medical Institutions. After the transaction is completed, the pharmaceutical companies return the price difference between the 'invoice price' and 'base price' to the Dealers.' 'The huge price difference is 'washed' and 'cashed out' through fraudulent invoicing methods, becoming a source of profit for illegal Dealers and commercial bribery, causing some pharmaceutical prices to be artificially inflated from the source.' The National Healthcare Security Administration is highly concerned about the above issues, firmly opposes inflated drug prices that increase the burden on patients, firmly opposes fraudulent invoices forming illegal profit chains, and firmly opposes illegal and irregular practices such as 'one drug with two prices' and 'sales with kickbacks.'